Evaluation of the safety of T-DXd in the Treatment of HER2-positive breast cancer

Abstract. Breast cancer (BC) is one of the most common diseases in women today, and HER2-positive BC has attracted the attention of researchers. Anti-her2 targeted therapy is an important tool in the treatment of HER2. In recent years, antibody-coupling drugs have entered people's field of vision and triggered a boom, and the research on T-DXd targeted therapy for HER2-positive BC is also gradually advancing and improving. This paper mainly discusses the mechanism of HER2-positive BC, explores the mechanism of action of T-DXd against HER2-positive BC, analyzes the side effects and safety evaluation of T-DXd targeted therapy for adult female patients with HER2-positive BC, and concludes that T-DXd is a relatively safe drug. However, it can be found that the pulmonary interstitial disease after treatment is a serious side effect that should not be ignored. Future studies can focus on discussing the principle of the side effect, ways to reduce the probability of its occurrence and more accurate and safe medication programs.